Volume 1 | Issue 3 | DOI: https://doi.org/10.33696/haematology.1.015
Citius, Altius, Fortius: Performance in a Bottle for CAR T-Cells
- 1Nucleus Biologics, LLC, San Diego, CA, USA
- 2Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
- 3Department of Pathology and Laboratory Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA, USA
Roddy S. O’Connor, firstname.lastname@example.org
Received Date: November 02, 2020
Accepted Date: November 25, 2020
Ayari A, O’Connor RS. Citius, Altius, Fortius: Performance in a Bottle for CAR T-Cells. J Clin Haematol. 2020; 1(3):103- 106.
Copyright: © 2020 Ayari A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Epidemiologic, Clinical, and Biological Characteristics of Adult T-cell Leukemia/Lymphoma in Martinique (1983- 2013)
Adult T-cell leukemia/lymphoma (ATL) was first described in the Southwest islands of Japan in 1977 . Then, the HTLV-1 (human T-lymphotropic virustype 1) was isolated in the United States in 1981 in two patients, one with mycosis fungoïdes and the other with Sezary syndrome [2,3], which have been consequently renamed.
The renewed interest in understanding how activated T cells alter their metabolism to support their growth and differentiation has led to several innovative advances in synthetic biology; culminating in a number of genetic and pharmacologic approaches aimed at improving the antitumor function of adoptively transferred T cells. Indeed, the growing field of immunometabolism has accelerated rapidly giving rise to exciting discoveries and exploratory studies revealing how T cells balance metabolic adaptations in response to intrinsic and extrinsic regulatory cues. Central to this body of work, we showed how chimeric antigen receptors (CAR)-induced metabolic reprogramming is an important determinant of efficacy and clinical outcome in blood-based malignancies.
Flavopiridol (Alvocidib), a Cyclin-dependent Kinases (CDKs) Inhibitor, Found Synergy Effects with Niclosamide in Cutaneous T-cell Lymphoma
Flavopiridol (FVP; alvocidib), an FDA-approved orphan drug, has been studied in clinical trials under both single treatment and combination scenarios; several singleagent Phase I and Phase II clinical trials against leukemia, lymphomas, and solid tumors are active. To date, there have been more than 50 clinical trials involving FVP in the United States. Unfortunately, almost half of patients on FVP clinical trials showed serious adverse effects, implicating appropriate dosages need to be found and an alternative way to circumvent the toxicity of FVP with synergistic agents.
Despite the variety of traditional methods available to treat cancer, such as surgical resection, chemotherapy, and radiation therapy, immunotherapy has emerged as an attractive alternative for cancer patients. Adoptive cell transfer (ACT) is a rapidly emerging immunotherapy approach, and a subcategory, genetically engineered T cells, which includes chimeric antigen receptor (CAR) T cells and T cell receptor (TCR)-modified T cells, has shown promising clinical benefits in treating malignant tumors .
Glycogen Synthase Kinase-3 (GSK-3) Regulation of Inhibitory Coreceptor Expression in T-cell Immunity
While the immune system is capable of recognizing tumor antigens, certain cancer cells evade immune detection and destruction .